MicuRx's MRX-1 comparable to linezolid

MicuRx Pharmaceuticals Inc. (Hayward, Calif.) said lead candidate MRX-1 was comparable to linezolid in a Chinese Phase II trial to treat complicated skin and soft tissue infections (cSSTI).

In a top-line analysis of 178 evaluable patients with Gram-positive bacterial infections, MicuRx said 96.5% of patients treated with 800 mg MRX-1 were clinically cured after 14 days, compared to 95.5% of those treated with 600 mg linezolid. ...